An Open, Baseline Controlled Evaluation of Sertraline
Safety and Efficacy in the Treatment of Depression in
Thai Patients
The SESS Group (Sertraline Efficacy and Safety Study Group)t
Affiliation : * Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200,
** Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, BangtQk 10700,
***Child Mental Health Center, Department of Mental Health, Ministry of Public Health, Bangkok 10400,
****Department of Psychiatry and Neurology. Pramongkutklao Hospital, Bangkok 10400,
***** Department of Psychiatry, Faculty of Medicine, Chulalongkom University, Bangkok 10330,
******Psychiatric Service. Taksin Hospital, Department of Medical Services, MOPH, Bangkok 10600, Thailand.
AbstractAn open, baseline controlled study of sertraline in depressed patients was conducted
in 6 treatment sites. Eighty-two patients between 20-82 years of age with DSM 111-R diagnosis
of a depressive illness received sertraline 50-200 mg/day. Among evaluable patients, there
was a significant reduction in depressive symptoms at the final visit. A statistically significant
change from baseline in Montgomery Asberg Depression Rating Scale (MADRS), Hospital
Anxiety Depression Rating Scale (HAD), and Clinical Global Impression Severity of Illness
Scale (CGI-S) scores was demonstrated. On the basis of MADRS criterion, 96.0 per cent of
patients responded and on the basis of CGI-S criterion, 86.6 per cent of patients responded. In
73.2 per cent of patients the final sertraline dosage was 50 mg. All-cause adverse events were
recorded in 35 patients (42.7%), whereas 22 (26.8%) had adverse events that were judged
treatment-related. The most frequently reported events were nausea and headache. Overall,
the patients tolerated sertraline very well. The results of the study suggest that sertraline is an
effective, well-tolerated and safe treatment for depression in Thai patients.
Keywords : Sertraline, Depression, Efficacy, Safety, Thai
All Articles
Download
